Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 1,391 Cr.
- Current Price ₹ 2,360
- High / Low ₹ 2,835 / 1,200
- Stock P/E 74.9
- Book Value ₹ 154
- Dividend Yield 0.06 %
- ROCE 41.3 %
- ROE 33.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 42.0%
- Promoter holding has increased by 1.05% over last quarter.
Cons
- Stock is trading at 15.3 times its book value
- Debtor days have increased from 56.6 to 87.4 days.
- Working capital days have increased from 15.5 days to 76.0 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|
| 12 | 18 | 25 | 45 | 64 | 73 | |
| 12 | 18 | 21 | 34 | 43 | 51 | |
| Operating Profit | 0 | 1 | 4 | 11 | 20 | 22 |
| OPM % | 3% | 4% | 17% | 23% | 32% | 30% |
| 1 | 1 | 1 | 2 | 4 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 1 | 1 | 5 | 11 | 23 | 25 |
| Tax % | 27% | 25% | 26% | 26% | 25% | |
| 1 | 1 | 3 | 8 | 17 | 19 | |
| EPS in Rs | 8.58 | 19.77 | 28.51 | 31.48 | ||
| Dividend Payout % | 0% | 0% | 0% | 3% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 51% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 158% |
| TTM: | 52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 73% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 42% |
| Last Year: | 33% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 1 | 1 | 1 | 6 |
| Reserves | 2 | 3 | 6 | 18 | 81 | 85 |
| 0 | 0 | 0 | 8 | 1 | 2 | |
| 3 | 8 | 9 | 8 | 15 | 17 | |
| Total Liabilities | 5 | 11 | 16 | 35 | 98 | 110 |
| 0 | 0 | 0 | 3 | 2 | 4 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 3 | 21 | 43 | 43 |
| 5 | 11 | 12 | 11 | 53 | 62 | |
| Total Assets | 5 | 11 | 16 | 35 | 98 | 110 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 1 | -0 | 5 | 5 | 2 | |
| -1 | -0 | -5 | -15 | -21 | |
| 0 | -0 | -0 | 12 | 39 | |
| Net Cash Flow | 1 | -0 | 0 | 2 | 21 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 50 | 71 | 43 | 39 | 87 |
| Inventory Days | 23 | 36 | 47 | 5 | 22 |
| Days Payable | 68 | 164 | 139 | 60 | 107 |
| Cash Conversion Cycle | 5 | -56 | -48 | -16 | 2 |
| Working Capital Days | 22 | -18 | -38 | 8 | 76 |
| ROCE % | 46% | 92% | 69% | 41% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
22 November 2024 - Remus Pharmaceuticals Limited has informed about Transcript of the Investors Conference Call H1 FY25
-
Analysts/Institutional Investor Meet/Con. Call Updates
15 November 2024 - Remus Pharmaceuticals Limited has informed about Link of Recording for Investors Conference Call H1 FY25 held on November 15, 2024
-
Investor Presentation
15 November 2024 - Remus Pharmaceuticals Limited has informed about Investor Presentation
-
Analysts/Institutional Investor Meet/Con. Call Updates
11 November 2024 - Remus Pharmaceuticals Limited has informed about Schedule of meet
-
Press Release (Revised)
9 November 2024 - Remus Pharmaceuticals Limited has informed regarding a revised press release dated November 09, 2024, titled REMUS PHARMACEUTICALS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE HALF YEAR …
Annual reports
Concalls
-
Nov 2024TranscriptNotesPPT
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing